Cancer treatment firm Sirtex Medical reported that strong sales of its SIR-Spheres drove fiscal fourth-quarter and year-end revenue growth.
For the fourth quarter (end-June 30), Sirtex had $113.4 million in revenue, up 28.5% compared with the fourth quarter of fiscal 2014. Full-year revenue reached $176.1 million, up 36% from the $129.3 million posted last fiscal year.
For the year, Sirtex had net profit of 40.3 million, up from 23.9 million in fiscal 2014.
Global dose sales of its SIR-Spheres yttrium-90 (Y-90) resin microspheres grew 20% in 2015, according to the firm. Sirtex Medical attributed the growth to greater acceptance of the microsphere by the oncology community and increased investment in its sales and marketing structure.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
